Anti-inflammatory and proresolving lipid mediators

Annual Review of Pathology: Mechanisms of Disease

Volumn 3, Issue , 2008, Pages 279-312

  Serhan, Charles N ^a   Yacoubian, Stephanie ^a   Yang, Rong ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Leukocytes; Lipoxins; Macrophages; Neutrophils; Omega 3 PUFAs; Protectins; Resolvins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; AUTACOID; CD59 ANTIGEN; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; GLUCOCORTICOID; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; RESOLVIN; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRAIN ISCHEMIA; COLITIS; CORNEA INJURY; ENDOTHELIUM CELL; HUMAN; IMMUNOREGULATION; INFLAMMATION; KIDNEY ISCHEMIA; LIPID METABOLISM; MACROPHAGE; NEUTROPHIL; NONHUMAN; PERIODONTITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REPERFUSION INJURY; REVIEW; SECOND MESSENGER; STEREOSPECIFICITY;

ANIMALS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIPOXINS; MICE; NEUTROPHILS;

EID: 41749090254     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathmechdis.3.121806.151409     Document Type: Review

References (134)

1. Cotran RS, Kumar V, Collins T, eds. 1999. Robbins Pathologic Basis of Disease. Philadelphia: WB. Saunders. 1425 pp.
2. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. 2001. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2:612-19
3. Calder PC. 2006. Long-chain polyunsaturated fatty acids and inflammation. Scand. J. Food Nutr. 50(S2):54-61
4. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, et al. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21:325-32
5. Serhan CN, ed. 2005. Special issue on lipoxins and aspirin-triggered lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 73:139-321
6. Morris T, Rajakariar R, Stables M, Gilroy DW. 2006. Not all eicosanoids are bad. Trends Pharmacol. Sci. 27:609-11
7. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192:1197-204
8. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, et al. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196:1025-37
9. Hong S, Gronert K, Devchand P, Moussignac RL, Serhan CN. 2003. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J. Biol. Chem. 278:14677-87
10. Serhan CN, Gotlinger K, Hong S, Lu Y, Siegelman J, et al. 2006. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 176:1848-59
11. Marcheselli VL, Hong S, Lukiw WJ, Hua Tian X, Gronert K, et al. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and proinflammatory gene expression. J. Biol. Chem. 278:43807-17
12. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, et al. 2005. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 115:2774-83
13. Serhan CN. 2007. Resolution phases of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25:101-37
14. Burr GO, Burr MM. 1929. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 82:345-67
15. James MJ, Proudman SM, Cleland LG. 2003. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukot. Essent. Fatty Acids 68:399-405
16. Calder PC. 2006. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83(Suppl.):1505-9
17. Hamazaki K, Itomura M, Sawazaki S, Hamazaki T. 2006. Fish oil reduces tooth loss mainly through its anti-inflammatory effects? Med. Hypotheses 67:868-70
18. GISSI-Prev. Investig. 1999. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 354:447-55
19. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, et al. 2002. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897-903
20. Harris WS, Reid KJ, Sands SA, Spertus JA. 2007. Blood omega-3 and trans fatty acids in middle-aged acute coronary syndrome patients. Am. J. Cardiol. 99:154-58
21. Michelson AM, McCord JM, Fridovich I, eds. 1977. Superoxide and Superoxide Dismutases. London: Academic
22. Halliwell B. 1977. Superoxide and hydroxylation reactions. In Superoxide and Superoxide Dismutases, ed. AM Michelson, JM McCord, I Fridovich, pp. 335-49. London: Academic
23. Morrow JD, Roberts LJ. 1997. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1-21
24. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. 1987. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237:1171-76
25. Serhan CN, Savill J. 2005. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 6:1191-97
26. Serhan CN. 2005. Mediator lipidomics. Prostaglandins Other Lipid Mediat. 77: 4-14
27. 4 receptor that is regulated by IL-13 and IFN-γ and inhibits TNF-α-induced IL-8 release. J. Exp. Med. 187:1285-94
28. 2+ increase in human bronchial epithelium. J. Biol. Chem. 278:10879-84
29. Levy BD, De Sanctis GT, Devchand PR, Kim E, Ackerman K, et al. 2003. Lipoxins and aspirin-triggered lipoxins in airway responses. Adv. Exp. Med. Biol. 525:19-23
30. Serhan CN. 1989. On the relationship between leukotriene and lipoxin production by human neutrophils: evidence for differential metabolism of 15-HETE and 5-HETE. Biochim. Biophys. Acta 1004:158-68
31. Bannenberg GL, Chiang N, Ariel A, Arita M, Tjonahen E, et al. 2005. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174:4345-55
32. Gilroy DW, Lawrence T, Perretti M, Rossi AG. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 3:401-16
33. González-Périz A, Planagumà A, Gronert K, Miquel R, López-Parra M, et al. 2006. Docosahexanenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J. 20:2537-39
34. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. 1999. Inducible cycloxygenase may have anti-inflammatory properties. Nature Med. 5:698-701
35. Rajakariar R, Yaqoob MM, Gilroy DW. 2006. COX-2 in inflammation and resolution. Mol. Interv. 6:199-207
36. Gilroy DW, Perretti M. 2005. Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr. Op. Pharmacol. 5:405-11
37. Ariel A, Fredman G, Sun YP, Kantarci A, Van Dyke TE, et al. 2006. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution via modulation of CCR5 expression. Nat. Immunol. 7:1209-16
38. Freire-de-Lima CG, Xiao YQ, Gardai SJ, Bratton DL, Schiemann WP, Henson PM. 2006. Apoptotic cells, through transforming growth factor-β, coordinately induce anti-inflammatory and suppress proinflammatory eicosanoid and NO synthesis in murine macrophages. J. Biol. Chem. 281:38376-84
39. Flower RJ. 1985. Cyclooxygenase inhibitors: an overview. In Prostaglandins, Leukotrienes and Lipoxins: Biochemistry, Mechanism of Action, and Clinical Applications, ed. JM Bailey, pp. 583-91. New York: Plenum
40. Flower RJ. 2006. Prostaglandins, bioassay and inflammation. Br. J. Pharmacol. 147:S182-92
41. Vane JR. 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, pp. 181-206. Stockholm: Almqvist & Wiksell
42. Samuelsson B. 1982. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. In Les Prix Nobel: Nobel Prizes, Presentations, Biographies and Lectures, pp. 153-74. Stockholm: Almqvist & Wiksell
43. Weissmann G. 2004. Pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 10(Suppl. 3):26-31
44. Chen M, Lam BK, Kanaoka Y, Nigrovic PA, Audoly LP, et al. 2006. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 203:837-42
45. 4 (ATL). Am. J. Physiol. 277:C870-77
46. 4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101:15178-83
47. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, et al. 2003. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host-defense. FASEB J. 17:652-59
48. 4 receptor (ALX) up-regulation. Biomed. Pharmacother. 61:81-85
49. Chiang N, Serhan CN, Dahlén SE, Drazen JM, Hay DWP, et al. 2006. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58:463-87
50. 4 analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 39:4761-68
51. 4. Impact of aspirin therapy. Circulation 86:56-63
52. 4. Nat. Med. 8:1018-23
53. Kieran NE, Maderna P, Godson C. 2004. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65:1145-54
54. Karp CL, Flick LM, Park KW, Softic S, Greer TM, et al. 2004. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 5:388-92
55. Mangino MJ, Brounts L, Harms B, Heise C. 2006. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 79:84-92
56. 4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34:14609-15
57. 4 receptor. J. Biol. Chem. 272:6972-78
58. 4 analogs. Prostaglandins Leukot. Essent. Fatty Acids 73:245-50
59. Parkinson JF. 2006. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm. Allergy Drug Targets 5:91-106
60. 4 accelerate resolution of allergic edema in Angiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia. J. Immunol. 164:1029-36
61. 4 stable analogues. J. Clin. Invest. 101:819-26
62. 4 inhibit tumor necrosis factor 1a-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med. 189:1923-29
63. Svensson CI, Zattoni M, Serhan CN. 2007. Lipoxins and aspirin-triggered lipoxin inhibit inflammatory pain processing. J. Exp. Med. 204:245-52
64. 4. J. Immunol. 166:3650-54
65. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR. 2000. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164:1663-67
66. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, et al. 2002. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13:2497-507
67. Rossi AG, Sawatzky DA, eds. 2007. The Resolution of Inflammation. Basel, Switz.: Birkhäuser Verlag AG. 250 pp.
68. Ward C, Dransfield I, Chilvers ER, Haslett C, Rossi AG. 1999. Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets. Trends Pharmacol. Sci. 20:503-9
69. Brezinski ME, Gimbrone MA Jr, Nicolaou KC, Serhan CN. 1989. Lipoxins stimulate prostacyclin generation by human endothelial cells. FEBS Lett. 245:167-72
70. 4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J. Exp. Med. 200:69-78
71. 4. J. Pharmacol. Exp. Ther. 300:385-92
72. 4 induces heme oxygenase-1 in endothelial cells. Am. J. Physiol. Cell Physiol. 289:C557-63
73. 4 analog attenuates lipopolysaccharide- induced acute lung injury in mice: the role of heme oxygenase-1. Anesth. Analg. 104:369-77
74. 4 in the rat heart. Prostaglandins Other Lipid Mediat. 83:89-98
75. 4 by pioglitazone and atorvastatin in the rat. Circulation 114:929-35
76. Birnbaum Y, Ye Y, Rosanio S, Tavackoli S, Hu ZY, et al. 2005. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc. Res. 65:345-55
77. Ye Y, Lin Y, Atar S, Huang MH, Perez-Polo JR, et al. 2006. Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions. Am. J. Physiol. Heart Circ. Physiol. 291:H1158-69
78. 4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones. Circulation 114:873-75
79. Lu Y, Hong S, Tjonahen E, Serhan CN. 2005. Mediator-lipidomics: databases and search algorithms for PUFA-derived mediators. J. Lipid Res. 46:790-802
80. Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, et al. 2005. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201:713-22
81. Sun YP, Oh SF, Uddin J, Yang R, Gotlinger K, et al. 2007. Resolvin D1 and its aspirin-triggered 17R epimer: stereochemical assignments, anti-inflammatory properties and enzymatic inactivation. J. Biol. Chem. 282:9323-34
82. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, et al. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102:7671-76
83. 4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 178:3912-17
84. Tjonahen E, Oh SF, Siegelman J, Elangovan S, Percarpio KB, et al. 2006. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13:1193-202
85. Duffield JS, Hong S, Vaidya V, Lu Y, Fredman G, et al. 2006. Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177:5902-11
86. Hasturk H, Kantarci A, Ohira T, Arita M, Ebrahimi N, et al. 2006. RvE1 protects from local inflammation and osteoclast mediated bone destruction in periodontitis. FASEB J. 20:401-3
87. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. 2004. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 101:8491-96
88. Gronert K, Maheshwari N, Khan N, Hassan IR, Dunn M, Schwartzman ML. 2005. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 280:15267-78
89. Hong S, Tjonahen E, Morgan EL, Yu L, Serhan CN, Rowley AF. 2005. Rainbow trout (Oncorhynchus mykiss) brain cells biosynthesize novel docosahexaenoic acid-derived resolvins and protectins: mediator lipidomic analysis. Prostaglandins Other Lipid Mediat. 78:107-16
90. Bannenberg G, Moussignac RL, Gronert K, Devchand P, Schmidt B, et al. 2004. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol. 143:43-52
91. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, et al. 2002. Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168:5260-67
92. Hudert CA, Weylandt KH, Wang J, Lu Y, Hong S, et al. 2006. Transgenic mice rich in endogenous n-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 103:11276-81
93. Van Dyke TE, Serhan CN. 2003. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 82:82-90
94. Serhan CN. 2004. Clues for new therapeutics in osteoporosis and periodontal disease: new roles for lipoxygenases? Expert Opin. Ther. Targets 8:643-52
95. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, et al. 2003. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J. Immunol. 171:6856-65
96. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, et al. 1996. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98:2201-8
97. Bazan NG. 2005. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 15:159-66
98. Basile DP, Donohoe D, Roethe K, Osborn JL. 2001. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am. J. Physiol. Renal Physiol. 281:F887-99
99. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E. 2005. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172:824-30
100. 4 regulates bronchial epithelial cell responses to acid injury. Am. J. Pathol. 168:1064-72
101. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, et al. 2007. Protectin D1 is generated in asthma and dampens airway inflammation and hyper-responsiveness. J. Immunol. 178:496-502
102. McGettigan P, Henry D. 2006. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296:1653-56
103. Bongartz T, Sutton AJ, Sweeting JJ, Buchan I, Matteson EL, Montori V. 2006. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275-85
104. De Bandt M, Saint-Marcoux B on behalf of the CRI. 2006. Tumour necrosis factor α blockade and the risk of vasculitis. Ann. Rheum. Dis. 65:1534-35
105. Hochman D, Wolff B. 2006. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296:2203
106. Gallin JI, Snyderman R. 1999. In Inflammation: Basic Principles and Clinical Correlates, pp. 1047-61. Philadelphia: Lippincott Williams & Wilkins
107. Collins T, ed. 2001. Leukocyte Recruitment, Endothelial Cell Adhesion Molecules, and Transcriptional Control: Insights for Drug Discovery. Boston: Kluwer Acad. 327 pp.
108. Gallin JI, Snyderman R, Fearon DT, Haynes BF, Nathan C, eds. 1999. Inflammation: Basic Principles and Clinical Correlates. Philadelphia: Lippincott Williams & Wilkins. 1360 pp.
109. Clària J, Serhan CN. 1995. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 92:9475-79
110. 4 stable analog displays a unique topical anti-inflammatory profile. J. Immunol. 169:7063-70
111. 4 on mesangioproliferative nephritis in rats. Prostaglandins Leukot. Essent. Fatty Acids 76:173-80
112. 4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. USA 101:15736-41
113. 4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J. Exp. Med. 183:137-46
114. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, et al. 2007. Increased dietary intake of omega-3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat. Med. 13:868-73
115. Kang JX, Wang J, Wu L, Kang ZB. 2004. Fat-1 mice convert n-6 to n-3 fatty acids. Nature 427:504
116. Xia S, Lu Y, Wang J, He C, Hong S, et al. 2006. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc. Natl. Acad. Sci. USA 103:12499-504
117. Salem N Jr, Litman B, Kim HY, Gawrisch K. 2001. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36:945-59
118. Lands WEM, ed. 1987. Proceedings of the AOCS Short Course on Polyunsaturated Fatty Acids and Eicosanoids. Champaign, IL: Am. Oil Chem. Soc.
119. Simopoulos AP, Leaf A, Salem N Jr. 1999. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J. Am. Coll. Nutr. 18:487-89
120. Arita M, Oh S, Chonan T, Hong S, Elangovan S, et al. 2006. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 281:22847-54
121. 4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 92:75-82
122. 4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. Allergy 49:230-34
123. 4 analogs. J. Clin. Invest. 101:1860-69
124. 4 stable analogs are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med. 185:1693-704
125. 4 inhibits edema in mice: implications for the antiedematogenic mechanism induced by aspirin. Prostaglandins Other Lipid Mediat. 80:123-35
126. 4 are regulatory signals for neural stem cell proliferation and differentiation. FASEB J. 20:1785-92
127. Jain A, Batista EL Jr, Serhan C, Stahl GL, Van Dyke TE. 2003. Role for periodontitis in the progression of lipid deposition in an animal model. Infect. Immun. 71:6012-18
128. Thomas E, Leroux JL, Blotman F, Gravis C. 1995. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm. Res. 44:121-24
129. Wallace JL, Fiorucci S. 2003. A magic bullet for mucosal protection. . . and aspirin is the trigger? Trends Pharmacol. Sci. 24:323-26
130. Kieran NE, Doran PP, Connolly SB, Greenan MC, Higgins DF, et al. 2003. Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int. 64:480-92
131. Munger KA, Montero A, Fukunaga M, Uda S, Yura T, et al. 1999. Transfection of rat kidney with human 15-lipoxygenase suppresses inflammation and preserves function in experimental glomerulonephritis. Proc. Natl. Acad. Sci. USA 96:13375-80
132. Ariel A, Li PL, Wang W, Tang WX, Fredman G, et al. 2005. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 280:43079-86
133. Bazan NG. 2006. Survival signaling in retinal pigment epithelial cells in response to oxidative stress: significance in retinal degenerations. Adv. Exp. Med. Biol. 572:531-40
134. Bürli RW, Xu H, Zou X, Muller K, Golden J, et al. 2006. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg. Med. Chem. Lett. 16:3713-18